Unlock instant, AI-driven research and patent intelligence for your innovation.

Process for making siponimod and intermediate thereof

a technology of siponimod and siponimod, which is applied in the preparation of oximes, halogenated hydrocarbon preparations, and sulfonic acid esters, etc., can solve the problems of reducing the yield of the process

Pending Publication Date: 2022-06-30
SYNTHON BV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is for a process to make a medication called Siponimod. The process involves reacting two different compounds to create a new compound, which is then transformed into Siponimod. The patent also describes different forms of the compounds used in the process. The technical effect of this patent is to provide a more efficient and reliable method for producing Siponimod.

Problems solved by technology

The disadvantages of the process disclosed in WO2013 / 113915 are:1. The process number of reaction steps to obtain siponimod from the compound (1) is high;2. The compounds (1) and (2) are obtained if form of oils.
The possibility to purify oily compound is limited, column purification is frequently used.Chromatographic purification steps are tedious and expensive process steps on an industrial scale;3. The overall yield of the process (calculated from compound (1)) is low, about 26% of the theoretical yield

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for making siponimod and intermediate thereof
  • Process for making siponimod and intermediate thereof
  • Process for making siponimod and intermediate thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of 4-(bromomethyl)-1-cyclohexyl-2-(trifluoromethyl)benzene

[0102]

[0103]3.2 g of (4-cyclohexyl-3-(trifluoromethyl)phenyl)methanol was mixed with 22 ml of toluene. To the solution 12.8 ml of Hydrobromic acid (33% sol. in AcOH) was added at 20° C.-25° C. dropwise in course of 10 minutes with stirring. Then, 1.3 ml of Acetic anhydride was added with stirring at 20° C.-25° C. The resulting mixture was stirred at 20° C.-25° C. for 21 hours. The mixture was cooled to 0-2° C. and 30 ml of water was slowly added while the temperature of the mixture was kept below 20° C. 60 ml of n-heptane was added and the mixture was allowed to warm to 20° C.-25° C. The phases were separated and the organic phase was washed consecutively with 30 ml of water, 30 ml of saturated aqueous NaHCO3 and 30 ml of water. The organic phase was mixed with 0.6 g of silica gel. The suspension was agitated for 20 minutes. The suspension was filtered and the filtrate was concentrated (40-50° C., 80 -->40 mbar, then 5-10°...

example 2

ethyl-4-(hydroxymethyl)phenyl)ethan-1-one oxime

[0104]

[0105]15 g of 1-(3-ethyl-4-(hydroxymethyl)phenyl)ethan-1-one was dissolved in 150 ml of methanol. The solution was cooled to 0-5° C. and 8.3 g sodium acetate followed by 7 g of hydroxylamine hydrochloride were added. The mixture was stirred at 0-5° C. for 5 minutes, the mixture was warmed to 20° C.-25° C. over approx. 70 minutes. The mixture was stirred for 110 minutes in total. The mixture was diluted with 150 ml of water at 20-25° C. and stirred for 20 minutes. Another 50 ml of water was added and the mixture was cooled to 0-2° C. It was stirred at this temperature for 1 hour. The formed solid was collected by filtration, washed with 25 ml of cold water and dried to provide 13.4 g (82% of the theoretical yield) of (E)-1-(3-ethyl-4-(hydroxymethyl)phenyl)ethan-1-one oxime as white solid, in 99.75% purity (HPLC in). XRPD of the obtained solid compound corresponds to XRPD pattern depicted in FIG. 1.

example 3

ethyl-4-(hydroxymethyl)phenyl)ethan-1-one oxime

[0106]

[0107]15 g of 1-(3-ethyl-4-(hydroxymethyl)phenyl)ethan-1-one was dissolved in 150 ml of methanol and 8.3 g sodium acetate followed by 7 g of hydroxylamine hydrochloride were added. The resulting mixture was stirred at 20° C.-25° C. for 60 minutes. The mixture was concentrated to the amount approx. 60 g. 150 ml of saturated aqueous NaHCO3 and 90 ml of ethyl acetate were added, the phases were separated and the aqueous phase was extracted twice with 90 ml of ethyl acetate. The combined organic phases were washed with 90 ml of water. The organic phase was dried using MgSO4, filtered and the filtrate was concentrated to approx. ½ of the original volume. It was diluted with 180 ml of toluene. The mixture was concentrated to the amount approximately 90 g. The suspension was stirred overnight at 20° C.-25° C. The mixture was filtrated and the obtained solid was dried to provide 14.11 g (86% of the theoretical yield) of (E)-1-(3-ethyl-4-(...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.

Description

BACKGROUND OF THE PRESENT INVENTION[0001]The present invention relates to an improved process for making the compound Siponimod.[0002]Siponimod, 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid of formula (I),is a lysophospholipid EDG1 (S1P1) receptor ligand that is useful for treatment of immunological disorders. Fumaric acid salt of siponimod is now ongoing pre-registration for use in the treatment secondary progressive multiple sclerosis.[0003]Siponimod was first disclosed in WO2004 / 103306 by Novartis. A process for preparation of Siponimod is disclosed in WO2013 / 113915 application. The process disclosed in WO2013 / 113915 application is depicted in following scheme:[0004]The disadvantages of the process disclosed in WO2013 / 113915 are:[0005]1. The process number of reaction steps to obtain siponimod from the compound (1) is high;[0006]2. The compounds (1) and (2) are obtained if form of oils. The possibility to purify oily c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D205/04C07C17/16C07C249/08C07C249/12C07C303/28
CPCC07D205/04C07C17/16C07C303/28C07C249/12C07C249/08C07C2601/14C07C309/66C07C251/52C07C251/48C07C22/08
Inventor KELTJENS, ROLFHYLSE, ONDREJPARTL, JIRI
Owner SYNTHON BV